| CAS NO: | 36322-90-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| 50g | 电议 |
| 100g | 电议 |
| Molecular Weight (MW) | 331.35 |
|---|---|
| Formula | C15H13N3O4S |
| CAS No. | 36322-90-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 66 mg/mL (199.2 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | Chemical Name: 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide InChi Key: QYSPLQLAKJAUJT-UHFFFAOYSA-N InChi Code: InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20) SMILES Code: CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3 |
| Synonyms | CP 16171; Piroxicam; Feldene; Pyroxycam; Roxicam; BAXO; CP16171; CP-16171 |
| In Vitro | In vitro activity: Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. Cell Assay: Urinary bladder cancer cell lines are treated with graded concentrations of carboplatin (0.05, 0.5 and 1 μM) and Piroxicam (CP-16171) (167, 333 and 500 μM) for 72 h to assess dose-response profiles. For the combination approach, 0.05 μM of carboplatin is used with 333 μM Piroxicam. Both drugs are freshly prepared before each experiment. An untreated control group (cells not exposed to carboplatin and Piroxicam) is used for all assays |
|---|---|
| In Vivo | Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. |
| Animal model | Dogs undergo tumor staging, including thoracic and abdominal radiography, cystography, ultrasonography, and cystoscopy (with collection of tissue samples) before treatment and after 4 weeks of Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p. o.) treatment. Dogs receive no other cancer treatment during the 4 weeks of Piroxicam (CP-16171) treatment. Tissue samples are immediately frozen in liquid nitrogen for PGE2 analysis or fixed in 10% neutral buffered formalin for immunohistochemical examination. Urine is also collected before and after Piroxicam treatment, aliquoted, and then stored at –80°C until analyzed |
| Formulation & Dosage | 0.3 mg/kg |
| References | J Neurochem. 2001 Jan;76(2):480-9; Carcinogenesis. 1997 Oct;18(10):1921-30. |
m.cnreagent.com